株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

増殖性硝子体網膜症(PVR):パイプライン製品の分析

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 302496
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
増殖性硝子体網膜症(PVR):パイプライン製品の分析 Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 34 Pages
概要

増殖性硝子体網膜症(PVR)は、網膜剥離時に傷が網膜の下あるいは上にできた時に起こり、網膜が治癒して元通りになるのを妨げます。リスク因子には眼内出血や、外傷による炎症、高度の近視、家族の病歴、糖尿病に起因するひどい炎症や合併症などがあります。

当レポートでは、増殖性硝子体網膜症(PVR)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

増殖性硝子体網膜症(PVR)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Novartis AG
  • Promedior, Inc.
  • RXi Pharmaceuticals Corporation

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9109IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Proliferative Vitreoretinopathy (PVR) - Overview
    • Proliferative Vitreoretinopathy (PVR) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
    • Novartis AG
    • Promedior Inc
    • RXi Pharmaceuticals Corp
  • Proliferative Vitreoretinopathy (PVR) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects
  • Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences
      • May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform
      • May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform
      • May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
      • May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H1 2017
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior Inc, H1 2017
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top